Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Restrictions on Cash and Cash Equivalents

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheet to the total amounts in the Condensed Consolidated Statement of Cash Flows as follows:

	September 30, 2020		September 30, 2019
Cash and cash equivalents	$	9,698	$	6,707
Restricted cash	206		206
Restricted cash in other assets	468		468
Cash, cash equivalents and restricted cash in the statement of cash flows	$	10,372	$	7,381

Fair Value and Net Carrying Value of Outstanding Convertible Notes

As of September 30, 2020, the fair value and the respective net carrying value of the outstanding Convertible Notes are as follows:

(in thousands)

	Fair Value	Net Carrying Value
2023 Series C Convertible Notes	27,531	30,992
2023 Series D Convertible Notes	10,500	47,419

Schedule of Earnings Per Share, Basic and Diluted

For the three and nine months ended September 30, 2020, the potential dilutive common stock equivalents have been excluded from the computation of diluted loss per share, as their effect would have been anti-dilutive.

(in thousands except shares and per share data) 

	Three months ended September 30,					Nine months ended September 30,
	2020			2019		2020			2019
Basic loss per share computation:
Net loss - basic and diluted	$	(510)		$	(7,113)	$	(41,678)		$	(19,826)
Weighted average common shares - basic and diluted	6,082,517		(*)	5,385,041		5,690,164		(**)	5,383,531
Basic and diluted loss per share	$	(0.08)		$	(1.32)	$	(7.32)		$	(3.68)

(*) In accordance with ASC 260-10-45-13, the Company includes the Warrants issued to its Term Loan lenders to purchase 134,667 shares of the Company’s common stock at an exercise price of $0.01 per share, from July 20, 2020 to September 30, 2020, in the number of outstanding shares used to calculate the basic and diluted loss per share for the three months ended September 30, 2020.

(**) In accordance with ASC 260-10-45-13, the Company includes the Warrants issued to its Term Loan lenders to purchase 134,667 shares of the Company's common stock at an exercise price of $0.01 per share from July 20, 2020 to September 30, 2020 and 538,995 shares of the Company’s common stock at an exercise of $0.01 per share from May 28, 2020 to September 30, 2020, in the number of outstanding shares used to calculate the basic and diluted loss per share for the nine months ended September 30, 2020.